ArticleEMBO molecular medicine2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers.
0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed
8.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed, 266 citations in OpenAlex.
- Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Ovarian Cancer-SpecificClinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Clinical Efficacy of Olaparib inJCO precision oncology · 2021Trial
- Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.Cancer discovery · 2021Trial
- Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.Nature communications · 2020Trial
- Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.The Journal of clinical investigation · 2026Review
- Article
- PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers.International journal of molecular sciences · 2026Review
- Comprehensive comparison of homologous recombination deficiency predictors in early-stage triple-negative breast cancer.Breast cancer research : BCR · 2026Article
- Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.NPJ breast cancer · 2026Article
- Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance.Experimental hematology & oncology · 2026Review
- Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance.Pharmaceutics · 2026Review
- RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.NPJ breast cancer · 2026Article
- Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18-gene panel.Molecular oncology · 2026Article
- The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.Cancer discovery · 2026Article
- The Genetic and Molecular Analyses of Rare Candidate GermlineInternational journal of molecular sciences · 2026Article
- Article
- Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers.Clinical and translational medicine · 2026Review
- Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 inhibition.PloS one · 2026Article
- CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC.Cancer research communications · 2026Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 11 institutions in 6 countries.
Marta Castroviejo-BermejoExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Cristina CruzExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Alba Llop-GuevaraExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Sara Gutiérrez-EnríquezOncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Mandy DucyGenome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada.
Yasir Hussein IbrahimExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Albert Gris-OliverExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Benedetta PellegrinoExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Alejandra BrunaCancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
Marta GuzmánExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Olga RodríguezExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Judit GruesoExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Sandra BonacheOncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Alejandro Moles-FernándezOncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Guillermo VillacampaOncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Cristina ViaplanaOncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Patricia GómezDepartment of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Maria VidalDepartment of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Vicente PegPathology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Xavier Serres-CréixamsDepartment of Radiology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Graham DellaireDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Jacques SimardCHU de Quebec - Université Laval Research Center, Genomics Center CHUL, Québec City, QC, Canada.
Paolo NuciforoCIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Isabel T RubioCIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Rodrigo DienstmannOncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain.
J Carl BarrettAstraZeneca, Waltham, MA, USA.
Carlos CaldasCancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
José BaselgaHuman Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cristina SauraDepartment of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Javier CortésCIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Olivier DéasXenTech, Evry, France.
Jos JonkersDivision of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-9264-9792
Jean-Yves MassonGenome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada.
Stefano CairoXenTech, Evry, France.
Jean-Gabriel JuddeXenTech, Evry, France.
Mark J O'ConnorOncology Innovative Medicines and Early Clinical Development Biotech Unit, AstraZeneca, Cambridge, UK.
Orland DíezOncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Judith BalmañaHigh Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain jbalmana@vhio.net vserra@vhio.net.ORCID 0000-0002-0762-6415
Violeta SerraExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain jbalmana@vhio.net vserra@vhio.net.ORCID 0000-0001-6620-1065
Vall d'Hebron Institute of Oncology · ESUniversitat Autònoma de Barcelona · ESInstituto de Salud Carlos III · ESUniversité Laval · CAUniversity of Cambridge · GBAstraZeneca (United Kingdom) · GBAstraZeneca (United States) · USDalhousie University · CAMemorial Sloan Kettering Cancer Center · USThe Netherlands Cancer Institute · NLUniversity of Parma · IT
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MCancer Research UK 16942NCI NIH HHS P30 CA008748
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are effective in cancers with defective homologous recombination DNA repair (HRR), including BRCA1/2-related cancers. A test to identify additional HRR-deficient tumors will help to extend their use in new indications. We evaluated the activity of the PARPi olaparib in patient-derived tumor xenografts (PDXs) from breast cancer (BC) patients and investigated mechanisms of sensitivity through exome sequencing,
Indexed as
Drug Resistance, NeoplasmAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsFemaleHeterograftsHomologous RecombinationHumansMicePhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsRad51 RecombinaseAntineoplastic AgentsBiomarkers, TumorolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsRAD51 protein, humanRad51 RecombinaseBRCA1homologous recombinationPALB2PARP inhibitorsRAD51
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.